Craig B Davis Selected Research

utomilumab

1/2022	Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.
1/2020	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas.
12/2019	A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
1/2018	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Craig B Davis Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 05/2003
2	Fatigue 01/2020 - 01/2018
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Carcinoma (Carcinomatosis) 12/2021
1	Lymphoma (Lymphomas) 01/2020
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2020

Drug/Important Bio-Agent (IBA)

4	utomilumabIBA 01/2022 - 01/2018
2	LigandsIBA 01/2022 - 12/2019
2	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2021
1	PerforinIBA 01/2022
1	Granzymes (Granzyme)IBA 01/2022
1	avelumabIBA 12/2021
1	Biomarkers (Surrogate Marker)IBA 12/2021
1	Rituximab (Mabthera)FDA Link 01/2020
1	CC ChemokinesIBA 12/2019
1	AntibodiesIBA 12/2019
1	Monoclonal AntibodiesIBA 12/2019
1	mogamulizumabIBA 12/2019
1	Transaminases (Aminotransferases)IBA 01/2018
1	CytokinesIBA 05/2003
1	Interleukin-2 (IL2)IBA 05/2003
1	Proteins (Proteins, Gene)FDA Link 05/2003

Therapy/Procedure

1	Immunotherapy 01/2022
1	Drug Therapy (Chemotherapy) 12/2021
1	Therapeutics 12/2021